Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-CTR-FAPI-30
- Development stage
- Unknown
- Lead developer
- Peking University-Tsinghua University Center for Life Sciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[68Ga]Ga-CTR-FAPI-30 is a gallium-68 labeled covalent targeted radioligand (CTR) designed to inhibit fibroblast activation protein (FAP). Unlike conventional FAP inhibitors (FAPIs) that bind reversibly to the target, CTR-FAPI-30 utilizes a covalent binding mechanism to form a stable, irreversible bond with the FAP enzyme. This approach is intended to enhance tumor retention and improve the target-to-background ratio in positron emission tomography (PET) imaging. It is primarily being developed as a diagnostic imaging agent for the precise localization of malignant lesions in medullary thyroid carcinoma (MTC), facilitating staging and surgical planning. Clinical data suggests it offers superior diagnostic accuracy, sensitivity, and specificity compared to conventional imaging modalities like CT and ultrasound.
- Other names
- Gallium-68 CTR-FAPI-30Gallium68 CTR-FAPI-30Gallium 68 CTR-FAPI-3068Ga-labeled covalent FAP inhibitor 30
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on [68Ga]Ga-CTR-FAPI-30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-CTR-FAPI-30.